Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer

スポンサーリンク

概要

• 論文の詳細を見る
• 2011-04-10

著者

• TANII Hiromi

  Novartis Pharma Japan

• Tanii Hiromi

  Novartis Pharma K.k.

• Nishio Makoto

  Cancer Institute Hospital

• HIDA Toyoaki

  Aichi Cancer Center Hospital

• TAMIYA Motohiro

  Osaka Prefectural Medical Center for Respiratory and Allergic Diseases

• YAMAMOTO Nobuyuki

  Shizuoka Cancer Center

• HIRASHIMA Tomonori

  Osaka Prefectural Medical Center for Respiratory and Allergic Diseases

• HORAI Takeshi

  Cancer Institute Hospital

• SHI Michael

  Novartis Pharmaceuticals Corporation

• KOBAYASHI Ken

  Novartis Pharma K.K.

• HORIO Yoshitsugu

  Aichi Cancer Center Hospital

関連論文

• A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
• Prediction of Sensitivity to STI571 among Chronic Myeloid Leukemia Patients by Genome-wide cDNA Microarray Analysis
• Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia : Results of a Japanese Phase II Clinical Study
• Multicenter Prospective Study of Interferon α versus Allogeneic Stem Cell Transplantation for Patients with New Diagnoses of Chronic Myelogenous Leukemia
• A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade^【○!R】, ICL670) in patients with transfusion-dependent anemias and iron-overload : a Phase I study in Japan
• Analysis of the Sma d3 gene in hematological malignancies
• Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer

スポンサーリンク